597 related articles for article (PubMed ID: 23293300)
1. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
[TBL] [Abstract][Full Text] [Related]
2. The potential of Sutherlandia frutescens for herb-drug interaction.
Fasinu PS; Gutmann H; Schiller H; James AD; Bouic PJ; Rosenkranz B
Drug Metab Dispos; 2013 Feb; 41(2):488-97. PubMed ID: 23209194
[TBL] [Abstract][Full Text] [Related]
3. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
4. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3.
Noé J; Portmann R; Brun ME; Funk C
Drug Metab Dispos; 2007 Aug; 35(8):1308-14. PubMed ID: 17470528
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
[TBL] [Abstract][Full Text] [Related]
6. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
[TBL] [Abstract][Full Text] [Related]
8. Interaction of digitalis-like compounds with liver uptake transporters NTCP, OATP1B1, and OATP1B3.
Gozalpour E; Greupink R; Wortelboer HM; Bilos A; Schreurs M; Russel FG; Koenderink JB
Mol Pharm; 2014 Jun; 11(6):1844-55. PubMed ID: 24754247
[TBL] [Abstract][Full Text] [Related]
9. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.
Annaert P; Ye ZW; Stieger B; Augustijns P
Xenobiotica; 2010 Mar; 40(3):163-76. PubMed ID: 20102298
[TBL] [Abstract][Full Text] [Related]
10. Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.
Jeong HU; Kwon M; Lee Y; Yoo JS; Shin DH; Song IS; Lee HS
Drug Des Devel Ther; 2015; 9():643-53. PubMed ID: 25653502
[TBL] [Abstract][Full Text] [Related]
11. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.
Treiber A; Schneiter R; Häusler S; Stieger B
Drug Metab Dispos; 2007 Aug; 35(8):1400-7. PubMed ID: 17496208
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Inhibitory Effects of APINACA on Human Major Cytochrome P450, UDP-Glucuronosyltransferase Enzymes, and Drug Transporters.
Kim S; Choi WG; Kwon M; Lee S; Cho YY; Lee JY; Kang HC; Song IS; Lee HS
Molecules; 2019 Aug; 24(16):. PubMed ID: 31430908
[TBL] [Abstract][Full Text] [Related]
13. Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes.
Dunkoksung W; Vardhanabhuti N; Siripong P; Jianmongkol S
Drug Metab Dispos; 2019 Oct; 47(10):1040-1049. PubMed ID: 31399508
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir.
Shebley M; Liu J; Kavetskaia O; Sydor J; de Morais SM; Fischer V; Nijsen MJMA; Bow DAJ
Drug Metab Dispos; 2017 Jul; 45(7):755-764. PubMed ID: 28483778
[TBL] [Abstract][Full Text] [Related]
15. Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.
Namour F; Desrivot J; Van der Aa A; Harrison P; Tasset C; van't Klooster G
Drug Metab Lett; 2016; 10(1):38-48. PubMed ID: 26693854
[TBL] [Abstract][Full Text] [Related]
16. Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III.
Bednarczyk D; Boiselle C
Xenobiotica; 2016; 46(5):457-66. PubMed ID: 26383540
[TBL] [Abstract][Full Text] [Related]
17.
Bleasby K; Fillgrove KL; Houle R; Lu B; Palamanda J; Newton DJ; Lin M; Chan GH; Sanchez RI
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745395
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Interaction of AB-FUBINACA with Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes and Drug Transporters.
Kim S; Kim DK; Shin Y; Jeon JH; Song IS; Lee HS
Molecules; 2020 Oct; 25(19):. PubMed ID: 33050066
[TBL] [Abstract][Full Text] [Related]
19. Sodium fluorescein is a probe substrate for hepatic drug transport mediated by OATP1B1 and OATP1B3.
De Bruyn T; Fattah S; Stieger B; Augustijns P; Annaert P
J Pharm Sci; 2011 Nov; 100(11):5018-30. PubMed ID: 21837650
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
